CovidFranceV1, Main, Exploration, bibRecord, 000581

Squalene-based multidrug nanoparticles for improved mitigation of uncontrolled inflammation in rodents.

Identifieur interne : 000581 ( Main/Exploration ); précédent : 000580; suivant : 000582

Squalene-based multidrug nanoparticles for improved mitigation of uncontrolled inflammation in rodents.

Auteurs : Flavio Dormont [France] ; Romain Brusini [France] ; Catherine Cailleau [France] ; Franceline Reynaud [France, Brésil] ; Arnaud Peramo [France] ; Amandine Gendron [France] ; Julie Mougin [France] ; Françoise Gaudin [France] ; Mariana Varna [France] ; Patrick Couvreur [France]

Source :

Science advances [ 2375-2548 ] ; 2020.

RBID : pubmed:32548259

Descripteurs français

KwdFr :
- Adénosine (administration et posologie), Adénosine (composition chimique), Animaux (MeSH), Antioxydants (administration et posologie), Antioxydants (composition chimique), Betacoronavirus (MeSH), Endotoxémie (induit chimiquement), Endotoxémie (traitement médicamenteux), Facteurs immunologiques (administration et posologie), Facteurs immunologiques (composition chimique), Femelle (MeSH), Infections à coronavirus (anatomopathologie), Infections à coronavirus (traitement médicamenteux), Infections à coronavirus (virologie), Lipopolysaccharides (pharmacologie), Modèles animaux de maladie humaine (MeSH), Mâle (MeSH), Nanoparticules (administration et posologie), Nanoparticules (composition chimique), Pandémies (MeSH), Pneumopathie virale (anatomopathologie), Pneumopathie virale (traitement médicamenteux), Pneumopathie virale (virologie), Résultat thérapeutique (MeSH), Souris (MeSH), Souris de lignée BALB C (MeSH), Souris de lignée C57BL (MeSH), Squalène (administration et posologie), Squalène (composition chimique), Syndrome de réponse inflammatoire généralisée (induit chimiquement), Syndrome de réponse inflammatoire généralisée (traitement médicamenteux), Systèmes de délivrance de médicaments (méthodes), alpha-Tocophérol (administration et posologie), alpha-Tocophérol (composition chimique).
MESH :
- administration et posologie : Adénosine, Antioxydants, Facteurs immunologiques, Nanoparticules, Squalène, alpha-Tocophérol.
- anatomopathologie : Infections à coronavirus, Pneumopathie virale.
- composition chimique : Adénosine, Antioxydants, Facteurs immunologiques, Nanoparticules, Squalène, alpha-Tocophérol.
- induit chimiquement : Endotoxémie, Syndrome de réponse inflammatoire généralisée.
- méthodes : Systèmes de délivrance de médicaments.
- pharmacologie : Lipopolysaccharides.
- traitement médicamenteux : Endotoxémie, Infections à coronavirus, Pneumopathie virale, Syndrome de réponse inflammatoire généralisée.
- virologie : Infections à coronavirus, Pneumopathie virale.
- Animaux, Betacoronavirus, Femelle, Modèles animaux de maladie humaine, Mâle, Pandémies, Résultat thérapeutique, Souris, Souris de lignée BALB C, Souris de lignée C57BL.

English descriptors

KwdEn :
- Adenosine (administration & dosage), Adenosine (chemistry), Animals (MeSH), Antioxidants (administration & dosage), Antioxidants (chemistry), Betacoronavirus (MeSH), Coronavirus Infections (drug therapy), Coronavirus Infections (pathology), Coronavirus Infections (virology), Disease Models, Animal (MeSH), Drug Delivery Systems (methods), Endotoxemia (chemically induced), Endotoxemia (drug therapy), Female (MeSH), Immunologic Factors (administration & dosage), Immunologic Factors (chemistry), Lipopolysaccharides (pharmacology), Male (MeSH), Mice (MeSH), Mice, Inbred BALB C (MeSH), Mice, Inbred C57BL (MeSH), Nanoparticles (administration & dosage), Nanoparticles (chemistry), Pandemics (MeSH), Pneumonia, Viral (drug therapy), Pneumonia, Viral (pathology), Pneumonia, Viral (virology), Squalene (administration & dosage), Squalene (chemistry), Systemic Inflammatory Response Syndrome (chemically induced), Systemic Inflammatory Response Syndrome (drug therapy), Treatment Outcome (MeSH), alpha-Tocopherol (administration & dosage), alpha-Tocopherol (chemistry).
MESH :
- chemical , administration & dosage : Adenosine, Antioxidants, Immunologic Factors, Squalene, alpha-Tocopherol.
- chemical , chemistry : Adenosine, Antioxidants, Immunologic Factors, Squalene, alpha-Tocopherol.
- administration & dosage : Nanoparticles.
- chemically induced : Endotoxemia, Systemic Inflammatory Response Syndrome.
- chemistry : Nanoparticles.
- drug therapy : Coronavirus Infections, Endotoxemia, Pneumonia, Viral, Systemic Inflammatory Response Syndrome.
- methods : Drug Delivery Systems.
- pathology : Coronavirus Infections, Pneumonia, Viral.
- chemical , pharmacology : Lipopolysaccharides.
- virology : Coronavirus Infections, Pneumonia, Viral.
- Animals, Betacoronavirus, Disease Models, Animal, Female, Male, Mice, Mice, Inbred BALB C, Mice, Inbred C57BL, Pandemics, Treatment Outcome.

Abstract

Uncontrolled inflammatory processes are at the root of numerous pathologies. Most recently, studies on confirmed COVID-19 cases have suggested that mortality might be due to virally induced hyperinflammation. Uncontrolled pro-inflammatory states are often driven by continuous positive feedback loops between pro-inflammatory signaling and oxidative stress, which cannot be resolved in a targeted manner. Here, we report on the development of multidrug nanoparticles for the mitigation of uncontrolled inflammation. The nanoparticles are made by conjugating squalene, a natural lipid, to adenosine, an endogenous immunomodulator, and then encapsulating α-tocopherol, as antioxidant. This resulted in high drug loading, biocompatible, multidrug nanoparticles. By exploiting the endothelial dysfunction at sites of acute inflammation, these multidrug nanoparticles delivered the therapeutic agents in a targeted manner, conferring survival advantage to treated animals in models of endotoxemia. Selectively delivering adenosine and antioxidants together could serve as a novel therapeutic approach for safe treatment of acute paradoxal inflammation.

DOI: 10.1126/sciadv.aaz5466
PubMed: 32548259
PubMed Central: PMC7274527

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 000D55
to stream Main, to step Curation: 000D55

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Squalene-based multidrug nanoparticles for improved mitigation of uncontrolled inflammation in rodents.</title>
<author><name sortKey="Dormont, Flavio" sort="Dormont, Flavio" uniqKey="Dormont F" first="Flavio" last="Dormont">Flavio Dormont</name>
<affiliation wicri:level="4"><nlm:affiliation>Institut Galien Paris-Sud, CNRS UMR 8612, Université Paris-Sud, Université Paris-Saclay, 92296 Châtenay-Malabry, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Institut Galien Paris-Sud, CNRS UMR 8612, Université Paris-Sud, Université Paris-Saclay, 92296 Châtenay-Malabry</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Châtenay-Malabry</settlement>
</placeName>
<orgName type="university">Université Paris-Sud</orgName>
</affiliation>
</author>
<author><name sortKey="Brusini, Romain" sort="Brusini, Romain" uniqKey="Brusini R" first="Romain" last="Brusini">Romain Brusini</name>
<affiliation wicri:level="4"><nlm:affiliation>Institut Galien Paris-Sud, CNRS UMR 8612, Université Paris-Sud, Université Paris-Saclay, 92296 Châtenay-Malabry, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Institut Galien Paris-Sud, CNRS UMR 8612, Université Paris-Sud, Université Paris-Saclay, 92296 Châtenay-Malabry</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Châtenay-Malabry</settlement>
</placeName>
<orgName type="university">Université Paris-Sud</orgName>
</affiliation>
</author>
<author><name sortKey="Cailleau, Catherine" sort="Cailleau, Catherine" uniqKey="Cailleau C" first="Catherine" last="Cailleau">Catherine Cailleau</name>
<affiliation wicri:level="4"><nlm:affiliation>Institut Galien Paris-Sud, CNRS UMR 8612, Université Paris-Sud, Université Paris-Saclay, 92296 Châtenay-Malabry, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Institut Galien Paris-Sud, CNRS UMR 8612, Université Paris-Sud, Université Paris-Saclay, 92296 Châtenay-Malabry</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Châtenay-Malabry</settlement>
</placeName>
<orgName type="university">Université Paris-Sud</orgName>
</affiliation>
</author>
<author><name sortKey="Reynaud, Franceline" sort="Reynaud, Franceline" uniqKey="Reynaud F" first="Franceline" last="Reynaud">Franceline Reynaud</name>
<affiliation wicri:level="4"><nlm:affiliation>Institut Galien Paris-Sud, CNRS UMR 8612, Université Paris-Sud, Université Paris-Saclay, 92296 Châtenay-Malabry, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Institut Galien Paris-Sud, CNRS UMR 8612, Université Paris-Sud, Université Paris-Saclay, 92296 Châtenay-Malabry</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Châtenay-Malabry</settlement>
</placeName>
<orgName type="university">Université Paris-Sud</orgName>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>School of Pharmacy, Federal University of Rio de Janeiro, 21944-59 Rio de Janeiro, Brazil.</nlm:affiliation>
<country xml:lang="fr">Brésil</country>
<wicri:regionArea>School of Pharmacy, Federal University of Rio de Janeiro, 21944-59 Rio de Janeiro</wicri:regionArea>
<placeName><settlement type="city">Rio de Janeiro</settlement>
<region type="state">État de Rio de Janeiro</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Peramo, Arnaud" sort="Peramo, Arnaud" uniqKey="Peramo A" first="Arnaud" last="Peramo">Arnaud Peramo</name>
<affiliation wicri:level="4"><nlm:affiliation>Institut Galien Paris-Sud, CNRS UMR 8612, Université Paris-Sud, Université Paris-Saclay, 92296 Châtenay-Malabry, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Institut Galien Paris-Sud, CNRS UMR 8612, Université Paris-Sud, Université Paris-Saclay, 92296 Châtenay-Malabry</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Châtenay-Malabry</settlement>
</placeName>
<orgName type="university">Université Paris-Sud</orgName>
</affiliation>
</author>
<author><name sortKey="Gendron, Amandine" sort="Gendron, Amandine" uniqKey="Gendron A" first="Amandine" last="Gendron">Amandine Gendron</name>
<affiliation wicri:level="4"><nlm:affiliation>Institut Galien Paris-Sud, CNRS UMR 8612, Université Paris-Sud, Université Paris-Saclay, 92296 Châtenay-Malabry, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Institut Galien Paris-Sud, CNRS UMR 8612, Université Paris-Sud, Université Paris-Saclay, 92296 Châtenay-Malabry</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Châtenay-Malabry</settlement>
</placeName>
<orgName type="university">Université Paris-Sud</orgName>
</affiliation>
</author>
<author><name sortKey="Mougin, Julie" sort="Mougin, Julie" uniqKey="Mougin J" first="Julie" last="Mougin">Julie Mougin</name>
<affiliation wicri:level="4"><nlm:affiliation>Institut Galien Paris-Sud, CNRS UMR 8612, Université Paris-Sud, Université Paris-Saclay, 92296 Châtenay-Malabry, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Institut Galien Paris-Sud, CNRS UMR 8612, Université Paris-Sud, Université Paris-Saclay, 92296 Châtenay-Malabry</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Châtenay-Malabry</settlement>
</placeName>
<orgName type="university">Université Paris-Sud</orgName>
</affiliation>
</author>
<author><name sortKey="Gaudin, Francoise" sort="Gaudin, Francoise" uniqKey="Gaudin F" first="Françoise" last="Gaudin">Françoise Gaudin</name>
<affiliation wicri:level="3"><nlm:affiliation>Plateforme d'Histologie Immunopathologie de Clamart (PHIC) Université Paris-Saclay, Inserm, CNRS, Institut Paris Saclay d'Innovation thérapeutique, 92296 Châtenay-Malabry, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Plateforme d'Histologie Immunopathologie de Clamart (PHIC) Université Paris-Saclay, Inserm, CNRS, Institut Paris Saclay d'Innovation thérapeutique, 92296 Châtenay-Malabry</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Châtenay-Malabry</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3"><nlm:affiliation>Université Paris-Saclay, Inserm, Inflammation, Microbiome and Immunosurveillance, 92140 Clamart, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Université Paris-Saclay, Inserm, Inflammation, Microbiome and Immunosurveillance, 92140 Clamart</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Clamart</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Varna, Mariana" sort="Varna, Mariana" uniqKey="Varna M" first="Mariana" last="Varna">Mariana Varna</name>
<affiliation wicri:level="4"><nlm:affiliation>Institut Galien Paris-Sud, CNRS UMR 8612, Université Paris-Sud, Université Paris-Saclay, 92296 Châtenay-Malabry, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Institut Galien Paris-Sud, CNRS UMR 8612, Université Paris-Sud, Université Paris-Saclay, 92296 Châtenay-Malabry</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Châtenay-Malabry</settlement>
</placeName>
<orgName type="university">Université Paris-Sud</orgName>
</affiliation>
</author>
<author><name sortKey="Couvreur, Patrick" sort="Couvreur, Patrick" uniqKey="Couvreur P" first="Patrick" last="Couvreur">Patrick Couvreur</name>
<affiliation wicri:level="4"><nlm:affiliation>Institut Galien Paris-Sud, CNRS UMR 8612, Université Paris-Sud, Université Paris-Saclay, 92296 Châtenay-Malabry, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Institut Galien Paris-Sud, CNRS UMR 8612, Université Paris-Sud, Université Paris-Saclay, 92296 Châtenay-Malabry</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Châtenay-Malabry</settlement>
</placeName>
<orgName type="university">Université Paris-Sud</orgName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32548259</idno>
<idno type="pmid">32548259</idno>
<idno type="doi">10.1126/sciadv.aaz5466</idno>
<idno type="pmc">PMC7274527</idno>
<idno type="wicri:Area/Main/Corpus">000D55</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000D55</idno>
<idno type="wicri:Area/Main/Curation">000D55</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000D55</idno>
<idno type="wicri:Area/Main/Exploration">000D55</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Squalene-based multidrug nanoparticles for improved mitigation of uncontrolled inflammation in rodents.</title>
<author><name sortKey="Dormont, Flavio" sort="Dormont, Flavio" uniqKey="Dormont F" first="Flavio" last="Dormont">Flavio Dormont</name>
<affiliation wicri:level="4"><nlm:affiliation>Institut Galien Paris-Sud, CNRS UMR 8612, Université Paris-Sud, Université Paris-Saclay, 92296 Châtenay-Malabry, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Institut Galien Paris-Sud, CNRS UMR 8612, Université Paris-Sud, Université Paris-Saclay, 92296 Châtenay-Malabry</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Châtenay-Malabry</settlement>
</placeName>
<orgName type="university">Université Paris-Sud</orgName>
</affiliation>
</author>
<author><name sortKey="Brusini, Romain" sort="Brusini, Romain" uniqKey="Brusini R" first="Romain" last="Brusini">Romain Brusini</name>
<affiliation wicri:level="4"><nlm:affiliation>Institut Galien Paris-Sud, CNRS UMR 8612, Université Paris-Sud, Université Paris-Saclay, 92296 Châtenay-Malabry, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Institut Galien Paris-Sud, CNRS UMR 8612, Université Paris-Sud, Université Paris-Saclay, 92296 Châtenay-Malabry</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Châtenay-Malabry</settlement>
</placeName>
<orgName type="university">Université Paris-Sud</orgName>
</affiliation>
</author>
<author><name sortKey="Cailleau, Catherine" sort="Cailleau, Catherine" uniqKey="Cailleau C" first="Catherine" last="Cailleau">Catherine Cailleau</name>
<affiliation wicri:level="4"><nlm:affiliation>Institut Galien Paris-Sud, CNRS UMR 8612, Université Paris-Sud, Université Paris-Saclay, 92296 Châtenay-Malabry, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Institut Galien Paris-Sud, CNRS UMR 8612, Université Paris-Sud, Université Paris-Saclay, 92296 Châtenay-Malabry</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Châtenay-Malabry</settlement>
</placeName>
<orgName type="university">Université Paris-Sud</orgName>
</affiliation>
</author>
<author><name sortKey="Reynaud, Franceline" sort="Reynaud, Franceline" uniqKey="Reynaud F" first="Franceline" last="Reynaud">Franceline Reynaud</name>
<affiliation wicri:level="4"><nlm:affiliation>Institut Galien Paris-Sud, CNRS UMR 8612, Université Paris-Sud, Université Paris-Saclay, 92296 Châtenay-Malabry, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Institut Galien Paris-Sud, CNRS UMR 8612, Université Paris-Sud, Université Paris-Saclay, 92296 Châtenay-Malabry</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Châtenay-Malabry</settlement>
</placeName>
<orgName type="university">Université Paris-Sud</orgName>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>School of Pharmacy, Federal University of Rio de Janeiro, 21944-59 Rio de Janeiro, Brazil.</nlm:affiliation>
<country xml:lang="fr">Brésil</country>
<wicri:regionArea>School of Pharmacy, Federal University of Rio de Janeiro, 21944-59 Rio de Janeiro</wicri:regionArea>
<placeName><settlement type="city">Rio de Janeiro</settlement>
<region type="state">État de Rio de Janeiro</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Peramo, Arnaud" sort="Peramo, Arnaud" uniqKey="Peramo A" first="Arnaud" last="Peramo">Arnaud Peramo</name>
<affiliation wicri:level="4"><nlm:affiliation>Institut Galien Paris-Sud, CNRS UMR 8612, Université Paris-Sud, Université Paris-Saclay, 92296 Châtenay-Malabry, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Institut Galien Paris-Sud, CNRS UMR 8612, Université Paris-Sud, Université Paris-Saclay, 92296 Châtenay-Malabry</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Châtenay-Malabry</settlement>
</placeName>
<orgName type="university">Université Paris-Sud</orgName>
</affiliation>
</author>
<author><name sortKey="Gendron, Amandine" sort="Gendron, Amandine" uniqKey="Gendron A" first="Amandine" last="Gendron">Amandine Gendron</name>
<affiliation wicri:level="4"><nlm:affiliation>Institut Galien Paris-Sud, CNRS UMR 8612, Université Paris-Sud, Université Paris-Saclay, 92296 Châtenay-Malabry, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Institut Galien Paris-Sud, CNRS UMR 8612, Université Paris-Sud, Université Paris-Saclay, 92296 Châtenay-Malabry</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Châtenay-Malabry</settlement>
</placeName>
<orgName type="university">Université Paris-Sud</orgName>
</affiliation>
</author>
<author><name sortKey="Mougin, Julie" sort="Mougin, Julie" uniqKey="Mougin J" first="Julie" last="Mougin">Julie Mougin</name>
<affiliation wicri:level="4"><nlm:affiliation>Institut Galien Paris-Sud, CNRS UMR 8612, Université Paris-Sud, Université Paris-Saclay, 92296 Châtenay-Malabry, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Institut Galien Paris-Sud, CNRS UMR 8612, Université Paris-Sud, Université Paris-Saclay, 92296 Châtenay-Malabry</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Châtenay-Malabry</settlement>
</placeName>
<orgName type="university">Université Paris-Sud</orgName>
</affiliation>
</author>
<author><name sortKey="Gaudin, Francoise" sort="Gaudin, Francoise" uniqKey="Gaudin F" first="Françoise" last="Gaudin">Françoise Gaudin</name>
<affiliation wicri:level="3"><nlm:affiliation>Plateforme d'Histologie Immunopathologie de Clamart (PHIC) Université Paris-Saclay, Inserm, CNRS, Institut Paris Saclay d'Innovation thérapeutique, 92296 Châtenay-Malabry, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Plateforme d'Histologie Immunopathologie de Clamart (PHIC) Université Paris-Saclay, Inserm, CNRS, Institut Paris Saclay d'Innovation thérapeutique, 92296 Châtenay-Malabry</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Châtenay-Malabry</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3"><nlm:affiliation>Université Paris-Saclay, Inserm, Inflammation, Microbiome and Immunosurveillance, 92140 Clamart, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Université Paris-Saclay, Inserm, Inflammation, Microbiome and Immunosurveillance, 92140 Clamart</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Clamart</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Varna, Mariana" sort="Varna, Mariana" uniqKey="Varna M" first="Mariana" last="Varna">Mariana Varna</name>
<affiliation wicri:level="4"><nlm:affiliation>Institut Galien Paris-Sud, CNRS UMR 8612, Université Paris-Sud, Université Paris-Saclay, 92296 Châtenay-Malabry, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Institut Galien Paris-Sud, CNRS UMR 8612, Université Paris-Sud, Université Paris-Saclay, 92296 Châtenay-Malabry</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Châtenay-Malabry</settlement>
</placeName>
<orgName type="university">Université Paris-Sud</orgName>
</affiliation>
</author>
<author><name sortKey="Couvreur, Patrick" sort="Couvreur, Patrick" uniqKey="Couvreur P" first="Patrick" last="Couvreur">Patrick Couvreur</name>
<affiliation wicri:level="4"><nlm:affiliation>Institut Galien Paris-Sud, CNRS UMR 8612, Université Paris-Sud, Université Paris-Saclay, 92296 Châtenay-Malabry, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Institut Galien Paris-Sud, CNRS UMR 8612, Université Paris-Sud, Université Paris-Saclay, 92296 Châtenay-Malabry</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Châtenay-Malabry</settlement>
</placeName>
<orgName type="university">Université Paris-Sud</orgName>
</affiliation>
</author>
</analytic>
<series><title level="j">Science advances</title>
<idno type="eISSN">2375-2548</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adenosine (administration & dosage)</term>
<term>Adenosine (chemistry)</term>
<term>Animals (MeSH)</term>
<term>Antioxidants (administration & dosage)</term>
<term>Antioxidants (chemistry)</term>
<term>Betacoronavirus (MeSH)</term>
<term>Coronavirus Infections (drug therapy)</term>
<term>Coronavirus Infections (pathology)</term>
<term>Coronavirus Infections (virology)</term>
<term>Disease Models, Animal (MeSH)</term>
<term>Drug Delivery Systems (methods)</term>
<term>Endotoxemia (chemically induced)</term>
<term>Endotoxemia (drug therapy)</term>
<term>Female (MeSH)</term>
<term>Immunologic Factors (administration & dosage)</term>
<term>Immunologic Factors (chemistry)</term>
<term>Lipopolysaccharides (pharmacology)</term>
<term>Male (MeSH)</term>
<term>Mice (MeSH)</term>
<term>Mice, Inbred BALB C (MeSH)</term>
<term>Mice, Inbred C57BL (MeSH)</term>
<term>Nanoparticles (administration & dosage)</term>
<term>Nanoparticles (chemistry)</term>
<term>Pandemics (MeSH)</term>
<term>Pneumonia, Viral (drug therapy)</term>
<term>Pneumonia, Viral (pathology)</term>
<term>Pneumonia, Viral (virology)</term>
<term>Squalene (administration & dosage)</term>
<term>Squalene (chemistry)</term>
<term>Systemic Inflammatory Response Syndrome (chemically induced)</term>
<term>Systemic Inflammatory Response Syndrome (drug therapy)</term>
<term>Treatment Outcome (MeSH)</term>
<term>alpha-Tocopherol (administration & dosage)</term>
<term>alpha-Tocopherol (chemistry)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adénosine (administration et posologie)</term>
<term>Adénosine (composition chimique)</term>
<term>Animaux (MeSH)</term>
<term>Antioxydants (administration et posologie)</term>
<term>Antioxydants (composition chimique)</term>
<term>Betacoronavirus (MeSH)</term>
<term>Endotoxémie (induit chimiquement)</term>
<term>Endotoxémie (traitement médicamenteux)</term>
<term>Facteurs immunologiques (administration et posologie)</term>
<term>Facteurs immunologiques (composition chimique)</term>
<term>Femelle (MeSH)</term>
<term>Infections à coronavirus (anatomopathologie)</term>
<term>Infections à coronavirus (traitement médicamenteux)</term>
<term>Infections à coronavirus (virologie)</term>
<term>Lipopolysaccharides (pharmacologie)</term>
<term>Modèles animaux de maladie humaine (MeSH)</term>
<term>Mâle (MeSH)</term>
<term>Nanoparticules (administration et posologie)</term>
<term>Nanoparticules (composition chimique)</term>
<term>Pandémies (MeSH)</term>
<term>Pneumopathie virale (anatomopathologie)</term>
<term>Pneumopathie virale (traitement médicamenteux)</term>
<term>Pneumopathie virale (virologie)</term>
<term>Résultat thérapeutique (MeSH)</term>
<term>Souris (MeSH)</term>
<term>Souris de lignée BALB C (MeSH)</term>
<term>Souris de lignée C57BL (MeSH)</term>
<term>Squalène (administration et posologie)</term>
<term>Squalène (composition chimique)</term>
<term>Syndrome de réponse inflammatoire généralisée (induit chimiquement)</term>
<term>Syndrome de réponse inflammatoire généralisée (traitement médicamenteux)</term>
<term>Systèmes de délivrance de médicaments (méthodes)</term>
<term>alpha-Tocophérol (administration et posologie)</term>
<term>alpha-Tocophérol (composition chimique)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Adenosine</term>
<term>Antioxidants</term>
<term>Immunologic Factors</term>
<term>Squalene</term>
<term>alpha-Tocopherol</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Adenosine</term>
<term>Antioxidants</term>
<term>Immunologic Factors</term>
<term>Squalene</term>
<term>alpha-Tocopherol</term>
</keywords>
<keywords scheme="MESH" qualifier="administration & dosage" xml:lang="en"><term>Nanoparticles</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Adénosine</term>
<term>Antioxydants</term>
<term>Facteurs immunologiques</term>
<term>Nanoparticules</term>
<term>Squalène</term>
<term>alpha-Tocophérol</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Endotoxemia</term>
<term>Systemic Inflammatory Response Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="chemistry" xml:lang="en"><term>Nanoparticles</term>
</keywords>
<keywords scheme="MESH" qualifier="composition chimique" xml:lang="fr"><term>Adénosine</term>
<term>Antioxydants</term>
<term>Facteurs immunologiques</term>
<term>Nanoparticules</term>
<term>Squalène</term>
<term>alpha-Tocophérol</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term>
<term>Endotoxemia</term>
<term>Pneumonia, Viral</term>
<term>Systemic Inflammatory Response Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="induit chimiquement" xml:lang="fr"><term>Endotoxémie</term>
<term>Syndrome de réponse inflammatoire généralisée</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Drug Delivery Systems</term>
</keywords>
<keywords scheme="MESH" qualifier="méthodes" xml:lang="fr"><term>Systèmes de délivrance de médicaments</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Lipopolysaccharides</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Lipopolysaccharides</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Endotoxémie</term>
<term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
<term>Syndrome de réponse inflammatoire généralisée</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Betacoronavirus</term>
<term>Disease Models, Animal</term>
<term>Female</term>
<term>Male</term>
<term>Mice</term>
<term>Mice, Inbred BALB C</term>
<term>Mice, Inbred C57BL</term>
<term>Pandemics</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Betacoronavirus</term>
<term>Femelle</term>
<term>Modèles animaux de maladie humaine</term>
<term>Mâle</term>
<term>Pandémies</term>
<term>Résultat thérapeutique</term>
<term>Souris</term>
<term>Souris de lignée BALB C</term>
<term>Souris de lignée C57BL</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Uncontrolled inflammatory processes are at the root of numerous pathologies. Most recently, studies on confirmed COVID-19 cases have suggested that mortality might be due to virally induced hyperinflammation. Uncontrolled pro-inflammatory states are often driven by continuous positive feedback loops between pro-inflammatory signaling and oxidative stress, which cannot be resolved in a targeted manner. Here, we report on the development of multidrug nanoparticles for the mitigation of uncontrolled inflammation. The nanoparticles are made by conjugating squalene, a natural lipid, to adenosine, an endogenous immunomodulator, and then encapsulating α-tocopherol, as antioxidant. This resulted in high drug loading, biocompatible, multidrug nanoparticles. By exploiting the endothelial dysfunction at sites of acute inflammation, these multidrug nanoparticles delivered the therapeutic agents in a targeted manner, conferring survival advantage to treated animals in models of endotoxemia. Selectively delivering adenosine and antioxidants together could serve as a novel therapeutic approach for safe treatment of acute paradoxal inflammation.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32548259</PMID>
<DateCompleted><Year>2020</Year>
<Month>07</Month>
<Day>07</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>07</Month>
<Day>07</Day>
</DateRevised>
<Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2375-2548</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>6</Volume>
<Issue>23</Issue>
<PubDate><Year>2020</Year>
<Month>06</Month>
</PubDate>
</JournalIssue>
<Title>Science advances</Title>
<ISOAbbreviation>Sci Adv</ISOAbbreviation>
</Journal>
<ArticleTitle>Squalene-based multidrug nanoparticles for improved mitigation of uncontrolled inflammation in rodents.</ArticleTitle>
<Pagination><MedlinePgn>eaaz5466</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1126/sciadv.aaz5466</ELocationID>
<Abstract><AbstractText>Uncontrolled inflammatory processes are at the root of numerous pathologies. Most recently, studies on confirmed COVID-19 cases have suggested that mortality might be due to virally induced hyperinflammation. Uncontrolled pro-inflammatory states are often driven by continuous positive feedback loops between pro-inflammatory signaling and oxidative stress, which cannot be resolved in a targeted manner. Here, we report on the development of multidrug nanoparticles for the mitigation of uncontrolled inflammation. The nanoparticles are made by conjugating squalene, a natural lipid, to adenosine, an endogenous immunomodulator, and then encapsulating α-tocopherol, as antioxidant. This resulted in high drug loading, biocompatible, multidrug nanoparticles. By exploiting the endothelial dysfunction at sites of acute inflammation, these multidrug nanoparticles delivered the therapeutic agents in a targeted manner, conferring survival advantage to treated animals in models of endotoxemia. Selectively delivering adenosine and antioxidants together could serve as a novel therapeutic approach for safe treatment of acute paradoxal inflammation.</AbstractText>
<CopyrightInformation>Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC).</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dormont</LastName>
<ForeName>Flavio</ForeName>
<Initials>F</Initials>
<Identifier Source="ORCID">0000-0001-7309-1853</Identifier>
<AffiliationInfo><Affiliation>Institut Galien Paris-Sud, CNRS UMR 8612, Université Paris-Sud, Université Paris-Saclay, 92296 Châtenay-Malabry, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Brusini</LastName>
<ForeName>Romain</ForeName>
<Initials>R</Initials>
<AffiliationInfo><Affiliation>Institut Galien Paris-Sud, CNRS UMR 8612, Université Paris-Sud, Université Paris-Saclay, 92296 Châtenay-Malabry, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Cailleau</LastName>
<ForeName>Catherine</ForeName>
<Initials>C</Initials>
<Identifier Source="ORCID">0000-0001-5773-3190</Identifier>
<AffiliationInfo><Affiliation>Institut Galien Paris-Sud, CNRS UMR 8612, Université Paris-Sud, Université Paris-Saclay, 92296 Châtenay-Malabry, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Reynaud</LastName>
<ForeName>Franceline</ForeName>
<Initials>F</Initials>
<Identifier Source="ORCID">0000-0002-9053-0931</Identifier>
<AffiliationInfo><Affiliation>Institut Galien Paris-Sud, CNRS UMR 8612, Université Paris-Sud, Université Paris-Saclay, 92296 Châtenay-Malabry, France.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>School of Pharmacy, Federal University of Rio de Janeiro, 21944-59 Rio de Janeiro, Brazil.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Peramo</LastName>
<ForeName>Arnaud</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Institut Galien Paris-Sud, CNRS UMR 8612, Université Paris-Sud, Université Paris-Saclay, 92296 Châtenay-Malabry, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Gendron</LastName>
<ForeName>Amandine</ForeName>
<Initials>A</Initials>
<Identifier Source="ORCID">0000-0002-1094-8810</Identifier>
<AffiliationInfo><Affiliation>Institut Galien Paris-Sud, CNRS UMR 8612, Université Paris-Sud, Université Paris-Saclay, 92296 Châtenay-Malabry, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Mougin</LastName>
<ForeName>Julie</ForeName>
<Initials>J</Initials>
<Identifier Source="ORCID">0000-0002-2118-860X</Identifier>
<AffiliationInfo><Affiliation>Institut Galien Paris-Sud, CNRS UMR 8612, Université Paris-Sud, Université Paris-Saclay, 92296 Châtenay-Malabry, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Gaudin</LastName>
<ForeName>Françoise</ForeName>
<Initials>F</Initials>
<AffiliationInfo><Affiliation>Plateforme d'Histologie Immunopathologie de Clamart (PHIC) Université Paris-Saclay, Inserm, CNRS, Institut Paris Saclay d'Innovation thérapeutique, 92296 Châtenay-Malabry, France.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Université Paris-Saclay, Inserm, Inflammation, Microbiome and Immunosurveillance, 92140 Clamart, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Varna</LastName>
<ForeName>Mariana</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Institut Galien Paris-Sud, CNRS UMR 8612, Université Paris-Sud, Université Paris-Saclay, 92296 Châtenay-Malabry, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Couvreur</LastName>
<ForeName>Patrick</ForeName>
<Initials>P</Initials>
<Identifier Source="ORCID">0000-0001-7961-5443</Identifier>
<AffiliationInfo><Affiliation>Institut Galien Paris-Sud, CNRS UMR 8612, Université Paris-Sud, Université Paris-Saclay, 92296 Châtenay-Malabry, France.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>06</Month>
<Day>05</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Sci Adv</MedlineTA>
<NlmUniqueID>101653440</NlmUniqueID>
<ISSNLinking>2375-2548</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000975">Antioxidants</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007155">Immunologic Factors</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008070">Lipopolysaccharides</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>7QWM220FJH</RegistryNumber>
<NameOfSubstance UI="D013185">Squalene</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>H4N855PNZ1</RegistryNumber>
<NameOfSubstance UI="D024502">alpha-Tocopherol</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>K72T3FS567</RegistryNumber>
<NameOfSubstance UI="D000241">Adenosine</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName>
<SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000241" MajorTopicYN="N">Adenosine</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000975" MajorTopicYN="N">Antioxidants</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016503" MajorTopicYN="N">Drug Delivery Systems</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019446" MajorTopicYN="N">Endotoxemia</DescriptorName>
<QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007155" MajorTopicYN="N">Immunologic Factors</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008070" MajorTopicYN="N">Lipopolysaccharides</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053758" MajorTopicYN="N">Nanoparticles</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013185" MajorTopicYN="N">Squalene</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018746" MajorTopicYN="N">Systemic Inflammatory Response Syndrome</DescriptorName>
<QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D024502" MajorTopicYN="N">alpha-Tocopherol</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year>
<Month>09</Month>
<Day>20</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>04</Month>
<Day>10</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>6</Month>
<Day>18</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>6</Month>
<Day>18</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>7</Month>
<Day>8</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32548259</ArticleId>
<ArticleId IdType="doi">10.1126/sciadv.aaz5466</ArticleId>
<ArticleId IdType="pii">aaz5466</ArticleId>
<ArticleId IdType="pmc">PMC7274527</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Crit Care Med. 2007 Sep;35(9 Suppl):S584-90</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17713413</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Crit Care. 2010;14(4):230</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20804578</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Res. 2017 Jun 1;77(11):2964-2975</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28416486</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Free Radic Biol Med. 1995 Dec;19(6):903-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8582667</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2018 Jul 10;115(28):E6467-E6476</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29941602</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Cell Physiol. 2008 Oct;217(1):207-14</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18481258</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Control Release. 2012 Jul 20;161(2):609-18</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21840355</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>FEBS Lett. 1998 Jun 12;429(2):139-42</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9650577</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Inflammation. 2000 Feb;24(1):33-44</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10704062</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Pharmacol Exp Ther. 2019 Apr;369(1):144-151</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30670479</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Angew Chem Int Ed Engl. 2017 Sep 11;56(38):11399-11403</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28643857</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Control Release. 2019 Aug 10;307:302-314</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31260754</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Sci Transl Med. 2012 Aug 8;4(146):146ra108</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22875828</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>World J Cardiol. 2014 Jun 26;6(6):462-77</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24976919</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Shock. 2014 Jan;41(1):3-11</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24346647</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Nanotechnol. 2014 Nov 24;9(12):1054-1062</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25420034</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMC Res Notes. 2014 Apr 12;7:233</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24725742</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Drug Targets Inflamm Allergy. 2005 Aug;4(4):471-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16101524</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 1996 Nov 15;157(10):4634-40</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8906843</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cytokine Growth Factor Rev. 2003 Dec;14(6):523-35</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14563354</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Front Immunol. 2019 Feb 26;10:308</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30863410</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Invest. 1997 Jun 15;99(12):2832-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9185504</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biol Chem. 2014 Feb;395(2):203-30</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24127541</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Surgery. 2004 May;135(5):536-43</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15118591</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Front Immunol. 2013 Apr 08;4:85</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23580000</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Immunol. 2017 Jul;17(7):407-420</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28436424</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Clin Nutr. 1991 Jan;53(1 Suppl):314S-321S</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1985404</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Chest. 2017 Jun;151(6):1229-1238</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27940189</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Pharmacol Exp Ther. 1998 Jul;286(1):142-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9655853</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Respir Cell Mol Biol. 2003 Oct;29(4):427-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14500253</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12351-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12209006</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Crit Care. 2011;15(5):230</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21996422</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biofactors. 1998;7(1-2):21-30</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9523025</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 2001 Dec 21;276(51):47950-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11602590</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Interferon Cytokine Res. 2009 Jun;29(6):313-26</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19441883</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Crit Care. 2017 Mar 28;21(1):78</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28351429</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Oxid Med Cell Longev. 2016;2016:5698931</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26881031</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Invest. 2006 Jul;116(7):1913-23</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16823489</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Commun. 2017 May 30;8:15678</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28555624</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Antimicrob Chemother. 2013 Feb;68(2):257-74</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23054997</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Burns. 2017 May;43(3):471-485</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28034666</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Exp Ther Med. 2015 Sep;10(3):915-920</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26622414</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Atherosclerosis. 2002 Jan;160(1):69-80</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11755924</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Theor Biol. 2003 Dec 21;225(4):531-40</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14615212</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 1993 Jul 1;151(1):389-96</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8326132</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arch Biochem Biophys. 2016 Apr 1;595:100-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27095224</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Mar 28;395(10229):1033-1034</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32192578</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Acta Physiol Scand. 1987 Feb;129(2):189-94</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3033995</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Infect Immun. 1993 Apr;61(4):1496-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8454355</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 2000 Mar 3;275(9):6259-66</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10692422</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biochem Mol Biol Int. 1993 Nov;31(4):693-700</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8298498</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Prog Cardiovasc Dis. 1989 Jul-Aug;32(1):73-97</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2664879</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Physiol Pharmacol. 2011 Dec;62(6):677-83</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22314571</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Drug Discov. 2008 Sep;7(9):759-70</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18758473</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Crit Care Med. 1996 Mar;24(3):392-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8625625</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Brésil</li>
<li>France</li>
</country>
<region><li>État de Rio de Janeiro</li>
<li>Île-de-France</li>
</region>
<settlement><li>Châtenay-Malabry</li>
<li>Clamart</li>
<li>Rio de Janeiro</li>
</settlement>
<orgName><li>Université Paris-Sud</li>
</orgName>
</list>
<tree><country name="France"><region name="Île-de-France"><name sortKey="Dormont, Flavio" sort="Dormont, Flavio" uniqKey="Dormont F" first="Flavio" last="Dormont">Flavio Dormont</name>
</region>
<name sortKey="Brusini, Romain" sort="Brusini, Romain" uniqKey="Brusini R" first="Romain" last="Brusini">Romain Brusini</name>
<name sortKey="Cailleau, Catherine" sort="Cailleau, Catherine" uniqKey="Cailleau C" first="Catherine" last="Cailleau">Catherine Cailleau</name>
<name sortKey="Couvreur, Patrick" sort="Couvreur, Patrick" uniqKey="Couvreur P" first="Patrick" last="Couvreur">Patrick Couvreur</name>
<name sortKey="Gaudin, Francoise" sort="Gaudin, Francoise" uniqKey="Gaudin F" first="Françoise" last="Gaudin">Françoise Gaudin</name>
<name sortKey="Gaudin, Francoise" sort="Gaudin, Francoise" uniqKey="Gaudin F" first="Françoise" last="Gaudin">Françoise Gaudin</name>
<name sortKey="Gendron, Amandine" sort="Gendron, Amandine" uniqKey="Gendron A" first="Amandine" last="Gendron">Amandine Gendron</name>
<name sortKey="Mougin, Julie" sort="Mougin, Julie" uniqKey="Mougin J" first="Julie" last="Mougin">Julie Mougin</name>
<name sortKey="Peramo, Arnaud" sort="Peramo, Arnaud" uniqKey="Peramo A" first="Arnaud" last="Peramo">Arnaud Peramo</name>
<name sortKey="Reynaud, Franceline" sort="Reynaud, Franceline" uniqKey="Reynaud F" first="Franceline" last="Reynaud">Franceline Reynaud</name>
<name sortKey="Varna, Mariana" sort="Varna, Mariana" uniqKey="Varna M" first="Mariana" last="Varna">Mariana Varna</name>
</country>
<country name="Brésil"><region name="État de Rio de Janeiro"><name sortKey="Reynaud, Franceline" sort="Reynaud, Franceline" uniqKey="Reynaud F" first="Franceline" last="Reynaud">Franceline Reynaud</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidFranceV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000581 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000581 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidFranceV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:32548259
   |texte=   Squalene-based multidrug nanoparticles for improved mitigation of uncontrolled inflammation in rodents.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:32548259" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidFranceV1

This area was generated with Dilib version V0.6.37.
Data generation: Tue Oct 6 23:31:36 2020. Site generation: Fri Feb 12 22:48:37 2021

	Serveur d'exploration sur la COVID en France
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur la COVID en France

Squalene-based multidrug nanoparticles for improved mitigation of uncontrolled inflammation in rodents.

Squalene-based multidrug nanoparticles for improved mitigation of uncontrolled inflammation in rodents.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki